Overview
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
Description
This is an open-label continuation study to provide access and assess the safety and tolerability of latozinemab in participants who have completed participation in their parent latozinemab study.
All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks (q4w).
Eligibility
Inclusion Criteria:
- Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker).
- Has successfully completed participation in their parent latozinemab study.
- Female participants must be nonpregnant and nonlactating.
- Male participants must agree to acceptable contraception use.
Exclusion Criteria:
- Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.
- Clinically significant heart disease, liver disease or kidney disease. History or evidence of clinically significant brain disease other than FTD.